Arcutis director granted RSUs and stock options
Arcutis Biotherapeutics director Terrie Curran reported equity compensation grants.
Rhea-AI Filing Summary
Arcutis Biotherapeutics director Terrie Curran reported equity compensation grants. Curran received 5,778 Restricted Stock Units in connection with service as a non-employee director at the 2026 annual stockholder meeting, with one share of common stock issuable per RSU upon vesting. The RSUs vest on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service, and settlement has been deferred under a prior RSU deferral election. Curran was also granted options covering 16,667 shares of common stock at a $21.23 exercise price, vesting 100% on the same schedule. Following these awards, Curran directly holds 23,526 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 22,445 shares
Grant/Award
2 txns
Insider
Curran Terrie
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 16,667 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 5,778 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 16,667 contracts (Direct);
Common Stock — 23,526 shares (Direct)
Footnotes (2)
- F1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 22, 2025, maintained by the Company.
- F2. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
Key Figures
RSUs granted: 5,778 units
Stock options granted: 16,667 options
Option exercise price: $21.23 per share
+5 more
8 metrics
RSUs granted
5,778 units
Equity award to non-employee director as of 2026 annual meeting
Stock options granted
16,667 options
Director grant on June 5, 2026
Option exercise price
$21.23 per share
Exercise price for 16,667 director stock options
Shares underlying options
16,667 shares
Common stock underlying the granted stock options
Director holdings after grant
23,526 shares
Common shares directly owned by Curran following reported awards
Option expiration
June 5, 2036
Expiry date of director stock options
RSU vesting reference date
June 5, 2026
Earlier of first anniversary or next annual meeting for vesting
Transaction code
A (grant/award acquisition)
Code for both RSU and option awards
Key Terms
Restricted Stock Units ("RSUs"), non-employee director, RSU Deferral Election Form, exercise price, +2 more
6 terms
Restricted Stock Units ("RSUs") financial
"Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
non-employee director financial
"granted in connection with the Reporting Person's service as a non-employee director"
RSU Deferral Election Form financial
"settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form"
exercise price financial
"Stock Option (right to buy) with a $21.23 exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"underlying shares subject to the option vest and become exercisable as to 100% on the earlier"
annual meeting of stockholders financial
"as of the Company's 2026 annual meeting of stockholders"
FAQ
What did Arcutis (ARQT) director Terrie Curran report in this Form 4?
Terrie Curran reported receiving equity compensation consisting of 5,778 Restricted Stock Units and 16,667 stock options. These awards relate to service as a non-employee director and follow standard vesting conditions tied to the company’s 2026 annual meeting and continued board service.
How many Arcutis (ARQT) RSUs were granted to Terrie Curran and when do they vest?
Curran received 5,778 Restricted Stock Units, each convertible into one Arcutis common share upon vesting. Vesting occurs on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual stockholder meeting, subject to continued board service through that date.
What stock options did Terrie Curran receive from Arcutis (ARQT)?
Curran was granted stock options for 16,667 shares of Arcutis common stock at a $21.23 exercise price. These options vest and become fully exercisable on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, contingent on continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
